Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Walgreens Boots Alliance, Inc.'s Expenses

BioMarin vs. Walgreens: A Decade of Cost Dynamics

__timestampBioMarin Pharmaceutical Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 201412976400054823000000
Thursday, January 1, 201515200800076691000000
Friday, January 1, 201620962000087477000000
Sunday, January 1, 201724178600089052000000
Monday, January 1, 2018315264000100745000000
Tuesday, January 1, 201935946600091915000000
Wednesday, January 1, 202052427200095905000000
Friday, January 1, 2021470515000104442000000
Saturday, January 1, 2022483669000104437000000
Sunday, January 1, 2023577065000112009000000
Monday, January 1, 2024580235000121134000000
Loading chart...

Data in motion

Cost Insights: BioMarin vs. Walgreens Boots Alliance

In the ever-evolving landscape of pharmaceuticals and retail, understanding cost dynamics is crucial. BioMarin Pharmaceutical Inc. and Walgreens Boots Alliance, Inc. offer a fascinating study in contrasts. From 2014 to 2023, BioMarin's cost of revenue surged by over 340%, reflecting its aggressive growth strategy in the biotech sector. In contrast, Walgreens Boots Alliance, a retail giant, maintained a steady increase, with costs rising by approximately 104% over the same period.

A Decade of Change

BioMarin's costs peaked in 2023, highlighting its commitment to innovation and expansion. Meanwhile, Walgreens' costs consistently climbed, reaching their zenith in 2024, underscoring its resilience in the retail market. Notably, 2024 data for BioMarin is missing, leaving room for speculation on its future trajectory.

These insights reveal the distinct paths of two industry leaders, each navigating their unique challenges and opportunities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025